Industry news that matters to you.  Learn more

Aethlon Medical and Exosome Sciences Announce Brain Research Discoveries

Aethlon Medical, Inc. (OTCQX:AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), recently announced that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.

One Mind for Research Receives Support from Wounded Warriors Project®

One Mind for Research announced recently that Wounded Warrior Project® (WWP) has pledged $3.5 million in support of One Mind’s “Gemini Program,” contingent upon One Mind securing additional funding. “The Gemini Program” is a multi-year study of Traumatic Brain Injury (TBI) and Post-Traumatic Stress (PTS).

One Mind is catalyzing collaboration between international research centers, industry, and government to accelerate the translation of basic science into breakthrough diagnostics and improved treatments for all brain diseases and injuries. The Gemini Program is the first major research project in this mission.

Scheduled to launch in 2013, this multi-country, multi-site program will create a large-scale database of individuals with TBI and PTS with rigorous biomarker (e.g., genetics, imaging) and clinical measures. Gemini will enroll and follow 3,000-5,000 patients with head trauma in a multiple year study. Research of this scale will yield results that can be very rapidly translated into improved patient outcomes.

“This grant marks a significant breakthrough for our organization,” said General Pete Chiarelli, (Ret.), Chief Executive Officer of One Mind for Research. “Our goal is to bring together public, private, and government resources to fund major new brain related research that can deliver vastly improved diagnostic tools and treatments to patients very quickly.”

Traumatic brain injury and post-traumatic stress are the signature wounds of the current war and we know first-hand the profound and life-altering challenges wounded veterans face because of their effects,” said Steve Nardizzi, Executive Director, Wounded Warrior Project. WWP’s mission is to honor and empower Wounded Warriors and it is our hope that research like this will provide critical insight to improve the lives of those living with these invisible wounds of war.”

TBI affects an estimated 10 million people worldwide and more than 1.7 million in the U.S. every year. Up to 360,000 veterans of the wars in Iraq and Afghanistan suffered brain injuries. Over 53,000 Americans die every year due to TBI, and an estimated 5.3 million have lifelong disabilities caused by TBI.

PTS is the most prevalent wound associated with over 12 years of war — 50 percent of our most seriously wounded have PTS. The overall scale of PTS is immense: it is estimated to affect 8 percent of the population (25 million Americans) during their lifetime.

“We are very appreciative of this generous support from Wounded Warrior Project because it is a strong validation of One Mind’s strategy of accelerating brain research that will directly lead to improved patient outcomes, beginning with TBI and PTS, which have become such a burden on soldiers, veterans, and our entire society,” added One Mind CEO Chiarelli.

Source: One Mind from Research

Researchers Find Evidence that Brain Compensates after Traumatic Injury

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have found that a special magnetic resonance imaging (MRI) technique may be able to predict which patients who have experienced concussions will improve. The results, which were presented this week at the annual meeting of the Radiological Society of North America (RSNA), suggest that, in some patients, the brain may change to compensate for the damage caused by the injury.

NextGen Files for Intellectual Property on Dementia Biomarkers

NextGen Group Plc (AIM: NGG), an AIM listed company providing biomarker discovery services and diagnostic assay development, announces that its subsidiary, NextGen Sciences Dx (NGSDx), has filed for intellectual property (IP) on a combination of protein biomarkers with the potential for diagnosing changes in cognition for patients with early-stage dementia.

NextGen’s New Diagnostics Company Established

NextGen Group Plc (AIM: NGG), an AIM listed company providing biomarker discovery and testing services has completed the establishment of its new diagnostics subsidiary company (NextGen Sciences Dx Inc.). The board of NextGen believes that the creation of the diagnostics business as a separate corporate entity is an important milestone in the transformation of the Group from solely providing outsourced research work to owning a portfolio of valuable intellectual property.